20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
Latest updates in the field of neurotrophic factors in Parkinson’s
Neurotrophic factors such as GDNF are still being actively investigated as a potential treatment for Parkinson’s, and alternative methods of delivery are currently being explored.
Press Release: Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
23 February 2024 Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s. The DAPA-PD trial will evaluate the safety and tolerability…
Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s.
Webinar: Women with Parkinson’s – addressing sex and gender gaps in research
To mark International Women’s Day, Cure Parkinson’s is hosting a webinar on 5 March at 8:00 pm – do join us for what promises to be a lively and thought-provoking discussion.
Spring Research Update meeting 2024: watch again
Our Spring Research Update Meeting once again took place at the renowned Royal Society of Medicine, Wimpole Street, London where we invited guests to an inspiring agenda of some of the most up to date news of our funded research. Theme: the impact of the…